SCHEMBL2547481

SCHEMBL2547481

Nc1ccnc(-c2nccs2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.53
ADORA2A P29274 4/20 0.49
ADORA1 P30542 3/20 0.44
PDPK1 O15530 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
NOS1 P29475 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RAB9A P51151 3/20 0.39
CYP2A6 P11509 1/20 0.38
TGFBR1 P36897 1/20 0.38
METAP1 P53582 1/20 0.37
GRB2 P62993 1/20 0.36
NPC1 O15118 2/20 0.36
PKM P14618 2/20 0.36
SYK P43405 2/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL7323075 0.81 HSP90AA1 (0.38) HSP90AA1ADORA2AADORA1PDPK1TSHR
SCHEMBL1489975 0.78 HSP90AA1 (0.54) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL27754726 0.76 HSP90AA1 (0.42) HSP90AA1NOS1GRB2KMT2AKDM4E
SCHEMBL6672732 0.74 CHEK2 (0.43) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL2068779 0.73 ALDH1A1 (0.56) ADORA2AADORA1ALDH1A1HSD17B10RAB9A
SCHEMBL23771960 0.73 ADORA2A (0.44) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL16815742 0.73 HSP90AA1 (0.41) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL23370176 0.73 ADORA2A (0.44) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL2549740 0.73 ADORA2A (0.49) HSP90AA1ADORA2AADORA1PDPK1LOXL2
SCHEMBL5017807 0.73 ADORA2A (0.49) HSP90AA1ADORA2AADORA1PDPK1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102892761-A 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists PALOBIOFARMA SL 2013-01-23 CN claimed
EP-2552909-B1 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS PALOBIOFARMA SL (ES) 2015-03-11 EP disclosed
US-8796284-B2 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists PALOBIOFARMA, S.L. (ES) 2014-08-05 US disclosed
US-20130053308-A1 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2013-02-28 US disclosed
EP-2552909-A1 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS Palobiofarma, S.L. (ES) 2013-02-06 EP disclosed
CN-102892761-A 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists PALOBIOFARMA SL 2013-01-23 CN disclosed
CN-101687863-B Amino-thiazolyl-pyrimidine derivatives and their use to treat cancer ASTRAZENECA AB 2012-09-12 CN disclosed
WO-2011121418-A1 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS PALOBIOFARMA, S.L. (ES) 2011-10-06 WO disclosed
CN-101687863-A Amino-thiazolyl-pyrimidine derivatives and their use to treat cancer ASTRAZENECA AB 2010-03-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053308-A1 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 HSP90AA1 3771/4885ADORA2A 1/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.